To read the full story, subscribe or sign in.

U.S. clearances granted for phase III trial of ranibizumab biosimilar Xlucane

Jan. 18, 2019

Bio Korea 2026 kicks off with spotlight on oligonucleotides

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...

AA meeting of minds as PTC, Novartis push votoplam in HD

BioWorld

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...

Innervation can slow, as well as speed, tumor growth, study finds

BioWorld

Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...

Glucagon-like peptide-1 receptor (GLP-1R) complex

Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

BioWorld

A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...